Fig. 4

Landscape of multiomics characteristics and DDR signatures in association with the two entities. A, E Clinical and multiomics subcategories in astrocytoma (A) and oligodendroglioma (E) with increased mRNAsi. B, F DDR signatures in astrocytoma (B) and oligodendroglioma (F) with increased tumor purity (Astrocytoma vs. oligodendroglioma in SGF: Wilcoxon P < 0.001, in TP53: Wilcoxon P < 0.001). C, G Mutation signatures of DDR in astrocytoma (C) and oligodendroglioma (G) with increased tumor purity. D, H Metabolic activities in astrocytoma (D) and oligodendroglioma (H) with increased tumor purity. I Relative expression of genes in the TP53 pathway in tumors. J. Relative expression of genes in the RB pathway in tumors. K Relative expression of genes in the RTK-PI3K pathway in tumors (Wilcoxon test, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant). L Schematic showing dual regulation of PTPN11 by EGFR and PDGFRA and their downstream substrates. mRNAsi mRNA-expression-based stemness classifiers